|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 263.50 DKK | +4.63% |
|
+10.67% | -18.99% |
| 08:20am | Lannebo Mixfond down 3.3 percent in March - divests Novo Nordisk, Hexagon and Axfood | FW |
| 04-15 | GoodRx Offering Novo Nordisk's Wegovy HD Weight Loss Drug | MT |
Main competitors
| Consensus | Analysts' target price evolution (4 months) | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Average Target P. | Objective/dr gap | Nbr of analysts | ||
|---|---|---|---|---|---|---|---|---|---|
 | 309.54 | +22.91% | 22 | ||||||
| 1,209.86 | +33.68% | 29 | ||||||
| 249.75 | +4.64% | 24 | ||||||
| 249 | +19.47% | 29 | ||||||
| 220.22 | +9.85% | 21 | ||||||
| 129.81 | +10.11% | 27 | ||||||
| 153.94 | +1.61% | 21 | ||||||
| 352.03 | +1.1% | 29 | ||||||
| 158.18 | +13.17% | 28 | ||||||
| 28.97 | +6.53% | 27 | ||||||
| 20.48 | -3.87% | 20 | ||||||
| 63.04 | +8.9% | 25 | ||||||
| 96.18 | +18.58% | 23 | ||||||
| 548.45 | +24.17% | 29 | ||||||
| 9,816.67 | +13.4% | 15 | ||||||
| 6,036.87 | +6.77% | 15 | ||||||
| 80.33 | +39.15% | 17 | ||||||
| 46.53 | +14.2% | 19 | ||||||
| 448.92 | +34.65% | 25 | ||||||
| Average | 1,064.15 | +14.68% | 23 | ||||||
| Weighted average by Cap. | 695.77 | +15.29% | 25 |
- Stock Market
- Equities
- NOVO B Stock
- Sector Novo Nordisk A/S
- Sector consensus
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition